Immunity

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

Retrieved on: 
Thursday, February 22, 2024

LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M. Matar, et. Al. [https://doi.org.10.1016/j.vaccine.2024.01.065] has been published in the peer-reviewed journal Vaccine, by Elsevier. The article is available at https://authors.elsevier.com/sd/article/S0264-410X(24)00077-X.

Key Points: 
  • [ https://doi.org.10.1016/j.vaccine.2024.01.065 ] has been published in the peer-reviewed journal Vaccine, by Elsevier.
  • The study described in the article used IMUNON’s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination.
  • DNA formulated with PlaCCine resulted in a DNA vaccine product that was stable for up to one year at 4°C.
  • Dr. Corinne Le Goff, president and chief executive officer of IMUNON, said, “The publication of this manuscript in the prestigious peer-reviewed journal Vaccine adds to the growing body of preclinical data confirming the efficacy and desirable features of our PlaCCine vaccine modality.

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Retrieved on: 
Tuesday, February 20, 2024

Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.

Key Points: 
  • Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.
  • The article, “Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing” appears in the “Cancer Immunity and Immunotherapy” section of the February (Volume 15) issue of the journal.
  • Additionally, combining sudocetaxel zendusortide with an anti-PD-L1 checkpoint inhibitor led to increases in tumor growth inhibition and median animal survival.
  • This realization supports the rationale for further exploration of the combination of sudocetaxel zendusortide with immunotherapy.”

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Retrieved on: 
Thursday, March 7, 2024

“I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points: 
  • “I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
  • This marks the first marketing approval milestone for CSL and Arcturus since signing the Collaboration and License agreement in November 2022.
  • In November 2023, Arcturus received Orphan Drug Designation from the U.S. FDA for ARCT-032, for the treatment of Cystic Fibrosis.
  • We have achieved a total of approximately $396.0 million in upfront payments and milestones from CSL as of December 31, 2023.

Simplifi Selects CyberProtonics for Work From Home Advanced Cybersecurity - Immediately Renders Hacked Data Unusable, Delivers First WFH Quantum Readiness

Retrieved on: 
Monday, March 4, 2024

CyberProtonics’ technology easily integrates with current security solutions, adding an indispensable layer of encryption that can render stolen data useless if a breach should occur.

Key Points: 
  • CyberProtonics’ technology easily integrates with current security solutions, adding an indispensable layer of encryption that can render stolen data useless if a breach should occur.
  • Simplifi’s business enablement platform is a perennial best-seller for WFH and provides advanced connectivity and communication tools that combine cellular connectivity with enterprise-grade cloud software.
  • Ensuring that data is protected wherever it resides is critical, including data residing with work from home and hybrid workplace employees.
  • CyberProtonics’ ability to maintain data protection into the future means we will be hearing more about their capabilities and accomplishments," Kolodgy said.

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Retrieved on: 
Monday, March 4, 2024

The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.

Key Points: 
  • The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.
  • Data from this Phase 1 clinical study will support future development across multiple indications.
  • Preclinical studies using models of AKI have demonstrated pretreatment with Gemini can reduce the severity and duration of AKI.
  • The start of this study is an important step toward bringing a potential new therapy for these unmet needs.”

CyberProtonics Redefines Data Protection with the Most Powerful, Lightweight, Quantum-Resistant Software-Based Cryptosystem for Digital Ecosystem, IoT and Generative AI

Retrieved on: 
Monday, March 4, 2024

CyberProtonics , trailblazers in quantum-resistant data protection, today introduced the first lightweight, software-based cryptosystem that makes being quantum-ready easy, affordable, and practical.

Key Points: 
  • CyberProtonics , trailblazers in quantum-resistant data protection, today introduced the first lightweight, software-based cryptosystem that makes being quantum-ready easy, affordable, and practical.
  • Legacy-friendly and plug-and-play features allow its cryptosystem to seamlessly integrate in all types of applications, including IoT, e-sim, and generative AI Private Large Language Models (PLLMs).
  • Internet of Things (IoT): CyberProtonics' cybersecurity protocols protect IoT devices and networks from the latest threats with reliable and robust security.
  • Generative AI: Large Language Models that companies want to keep private are protected by CyberProtonics’ proprietary cryptosystem.

Mountain Valley MD Provides Business Update, Appoints New CFO

Retrieved on: 
Friday, March 1, 2024

The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.

Key Points: 
  • The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.
  • To date, the Company has worked on a range of formulations for Quicksome™-powered product applications, including sleep, energy, appetite suppressant, cognition, immunity, calm, and pain relief.
  • The Company believes this will be valuable in its business development efforts and broad growth plans for its nutraceutical line of business.
  • Since July 2009, his tenure at Malaspina Consultants Inc. has been marked by CFO and accounting roles for various public and private companies across multiple industries.

Statement by Mobile Infirmary and The Center for Reproductive Medicine

Retrieved on: 
Thursday, March 7, 2024

MOBILE, Ala., March 7, 2024 /PRNewswire/ -- Mobile Infirmary, an affiliate of Infirmary Health, announces today that The Center for Reproductive Medicine will not restart in vitro fertilization procedures following a bill signed Wednesday night by Gov.

Key Points: 
  • MOBILE, Ala., March 7, 2024 /PRNewswire/ -- Mobile Infirmary, an affiliate of Infirmary Health, announces today that The Center for Reproductive Medicine will not restart in vitro fertilization procedures following a bill signed Wednesday night by Gov.
  • Kay Ivey.
  • "Based upon the language of the law, we are not reopening until we have legal clarification on the extent of immunity provided by the new Alabama law.
  • At this time, we believe the law falls short of addressing the fertilized eggs currently stored across the state and leaves challenges for physicians and fertility clinics trying to help deserving families have children of their own," stated Hannah Peterson, spokesperson for Mobile Infirmary.

First Day Introduces Women's Good Gut - The World's 1st Women's Gummy 3-in-1 Pre+ Post+ Probiotic!

Retrieved on: 
Thursday, March 7, 2024

AUSTIN, Texas, March 7, 2024 /PRNewswire-PRWeb/ -- First Day, the brand trusted for its innovative line of multivitamins for kids, teens, women, and men, announced today the launch of a groundbreaking product: Women's Good Gut. The world's first tri-biotic designed specifically to address digestive, immune, and vaginal health concerns in women aged 18 and above. A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being. Spearheaded by CEO and Founder, Alice Li, this revolutionary supplement marks a significant milestone in women's wellness.

Key Points: 
  • A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being.
  • A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being.
  • Women's Good Gut is now available for purchase on the First Day website ( www.firstday.com ), offering women a holistic approach to gut health and well-being.
  • Join the movement towards optimal wellness with Women's Good Gut from First Day.

Mānuka Health, Global Leader in Mānuka Honey, Launches Three Product Collections Designed for Holistic Inner and Outer Wellbeing

Retrieved on: 
Thursday, March 7, 2024

AUCKLAND, N.Z., March 7, 2024 /PRNewswire/ -- Mānuka Health, a global leader in premium mānuka honey products, is excited to announce the launch of three new product collections, inclusive of the brand's first skincare range. As the first prestige beauty and wellness brand to masterfully capture the complete spectrum of benefits from raw mānuka honey, propolis, and royal jelly, these new collections present one harmonious system designed to elevate vitality, reinforce resilience, and inspire complete wellbeing.

Key Points: 
  • Mānuka Health's new collections mirrors the intricate relationship between the European Honeybee pollinating amidst the blooms of the New Zealand mānuka tree.
  • The brand harvests their raw mānuka honey from the rich soils of New Zealand with brand-owned hives that ensure the utmost purity and quality.
  • Their unparalleled potency, individually and together, supports simplicity in a daily wellbeing routine for inner harmony and outer radiance.
  • All Mānuka Health's MGO mānuka honey is certified for authenticity, sustainably sourced, GMO-free, and raw and unpasteurized for exceptional benefits.